Mangoceuticals (MGRX) investor relations material

Executive summary

• Reported a net loss of $20.6 million for 2025, up from $8.7 million in 2024, driven by higher stock-based compensation, investor relations, and general expenses.

• Revenues declined to $456,021 in 2025 from $615,873 in 2024, mainly due to platform transition issues.

• The company continues to focus on men's wellness products via telemedicine, including ED, hair loss, hormone, and weight management treatments.

• Ongoing need for additional funding to support operations and growth, with substantial doubt about ability to continue as a going concern.

Financial highlights

• Revenues: $456,021 in 2025, down from $615,873 in 2024.

• Net loss: $20,643,455 in 2025, compared to $8,707,226 in 2024.

• Cash on hand: $1,486,338 at year-end 2025, up from $58,653 at year-end 2024, mainly due to financing activities.

• Stock-based compensation increased to $10.8 million in 2025 from $2.4 million in 2024.

• Working capital of $0.7 million at year-end 2025.

• Accumulated deficit reached $40.6 million as of December 31, 2025.

Outlook and guidance

• Management anticipates the need for additional funding to continue operations and execute growth strategy over the next 12 months.

• Plans to expand product offerings, enhance technology, and pursue strategic acquisitions, funding permitting.

• Strategic alternatives, including mergers or business combinations, are being evaluated to maximize shareholder value.